Vivek Mittal, PhD

Ford-Isom Research Professor of Cardiothoracic Surgery

Cardiothoracic Surgery

Contact & profiles

vim2010@med.cornell.edu

Appointments

Professor of Cell and Developmental Biology in Cardiothoracic SurgeryPrimary
Cardiothoracic Surgery · 2016–
Ford-Isom Research Professor of Cardiothoracic Surgery
Cardiothoracic Surgery · 2020–
Professor
Weill Cornell Graduate School — Cell & Developmental Biology · 2009–

Past Appointments

Professor of Cell and Developmental Biology
Cell and Developmental Biology · 2016–2025
Associate Professor of Cell and Developmental Biology in Cardiothoracic Surgery
Cardiothoracic Surgery · 2009–2016
Associate Professor of Cell and Developmental Biology
Cell and Developmental Biology · 2009–2016

Show all 5

Assistant Professor of Cell Biology in Cardiothoracic Surgery (Interim)
Cardiothoracic Surgery · 2008–2009
Assistant Professor of Cell and Developmental Biology (Interim)
Cell and Developmental Biology · 2008–2009

Centers

Clinical & Translational Science Center
Englander Institute for Precision Medicine
Sandra and Edward Meyer Cancer Centerresearch
Cancer Biology

Education

Ph.D.
Jawaharlal Nehru University (India), 1994
M.Sc.
Jawaharlal Nehru University (India), 1988
B.Sc.
St. Joseph's College (India), 1985

Highlights

1
Nature immunology · 2024
LYLiron Yoffe YHYongfeng He DCDing Cheng Gao MLM. Laura Martin+4 more →VMVivek Mittal
PMID: 39327500PMCID: PMC12636053DOISenior author57 citations
2
Nature communications · 2021
YBYang Bai SCSuzanne Cloonan DCDing Cheng Gao VMVivek Mittal
PMID: 34911956PMCID: PMC8674260DOISenior author281 citations
3
Nature cancer · 2021
NKNasser K Altorki DCDing Cheng Gao VMVivek Mittal
PMID: 34917944PMCID: PMC8670735DOISenior author58 citations

Publications

115

Funding

49 View NIH portfolio on RePORTER ↗

Active

15 grants

Sub-PI
Therapeutic targeting of the tumor microenvironment in triple negative breast cancer patients at high risk of relapse and preclinical models of lung metastases
National Cancer Institute · 2025–2030 · via Dartmouth-Hitchcock Medical Center
R01CA290013-02
Co-I
Discovery of a stem cell driving breast cancer spine metastases
National Cancer Institute · 2024–2029
R01CA282815-01A1
PI
Therapeutic targeting of the tumor microenvironment in triple negative breast cancer patients at high risk of relapse and preclinical models of lung metastases
U.S. Department of Defense · 2025–2029
HT9425-25-1-0401
MPI
Immunogenicity of lipid nanoparticles
National Institute of Allergy and Infectious Diseases · 2024–2028 · via Cornell University - Ithaca
R01AI178125-03
Co-I
PICI Grant and Main Collaboration Agreement with Multiple Subprojects
Parker Institute for Cancer Immunotherapy · 2024–2028
PICI 235170-01
MPI
ER stress-driven IRE1a-XBP1 signaling in lung cancer
National Cancer Institute · 2023–2028
R01CA271619-04
MPI
Immunoregulatory role of lung-resident club cell factors in lung cancer
National Cancer Institute · 2023–2028
R01CA271545-04
MPI
CAP-IT Center for LNP RNA Immunoprevention
National Cancer Institute · 2022–2027
U54CA272688-05
Co-I
Dynamics of Immune Response in Irradiated Rectal Cancer
National Cancer Institute · 2022–2027
U54CA274291-01
PI
Copper-Mediated Metabolic Reprogramming And ECM Alterations In TNBC Metastasis
National Cancer Institute · 2021–2027
R01CA257254-05
KP
Elucidating the oncogenic role of EMSY in non-small cell lung cancer
U.S. Department of Defense · 2024–2026
HT9425-24-1-0019
KP
Genetically engineered stem cell like T cells for the treatment of NSCLC
American Association for Thoracic Surgery · 2024–2026
AATS 235502-01
KP
To study the EMT contributions in tumor metastasis and chemoresistance by using lineage tracing models
National Cancer Institute · 2020–2026
R01CA244413-05
KP
Evaluating Lymph Node T Cell "Clonal Replacement" in a Phase II Trial of Neoadjuvant SBRT plus Cemiplimab versus Chemotherapy plus Cemiplimab in Resectable NSCLC
WCM Sandra and Edward Meyer Cancer Center · 2025–2026
MCC CTIF 250906-01
Co-I
Targeting cytidine deaminase-induced chromosomal instability as a driver of metastasis in bladder cancer
Starr Cancer Consortium · 2023–2025
I16-0054

Completed grants (34)

KP
Targeting APOBEC3A-induced chromosomal instability as a driver of metastasis in bladder cancer
U.S. Department of Defense · 2023–2025
HT9425-23-1-0790
KP
Modulation of CD8+ T cell differentiation and anti-tumor immunity by metabolic manipulation
National Center for Advancing Translational Sciences · 2024–2025
R03TR004611-01A1
PI
Targeting IL-1RAP to overcome EGFR-TKIs resistance in EGFR mutant NSCLC
Cantargia AB · 2021–2025Contract
SRA 213491-02
KP
T cells selected from lymph node acquisition for adoptive cell treatment of solid tumors
Daedalus Fund for Innovation (Weill Cornell) · 2024–2025BioPharma Alliance
BP 242177-01
KP
Characterizing T cell PD-1 response in the tumor draining lymph nodes of early-stage NSCLC patients
International Association for the Study of Lung Cancer · 2023–2025
IA 230418-01
MPI
Intercepting progression from pre-invasive to invasive lung adenocarcinoma
National Cancer Institute · 2019–2025· 2 renewals
UG3CA244697-01
MPI
MSK Spore in Genomic Instability in Breast Cancer
National Cancer Institute · 2024–2024 · via Memorial Sloan Kettering Cancer Center
P50CA247749-04
KP
Determine Mechanisms by Which Club Cell Factor/s Inhibit Myeloid-derived Suppressor Cells to Increase Efficacy of Immunotherapy in Lung Cancer
PhRMA Foundation · 2023–2024
PF 230234-01
KP
Tumor draining lymph node immunomodulation to decrease recurrence in NSCLC
LUNGevity Foundation · 2022–2024
LF 2022-13
KP
Targeting ART1, a novel immune checkpoint, for the treatment of lung cancer
U.S. Department of Defense · 2019–2023
W81XWH-19-1-0422
PI
Examining the link between EZH2 and chromosomal instability in metastatic breast cancer
Starr Cancer Consortium · 2021–2023
SCC I14-0036
PI
Addgene 704082
Addgene, Inc. · 2022–2023
Addgene 704082
PI
Addgene 698979
Addgene, Inc. · 2022–2023
Addgene 698979
PI
Targeting tumor intrinsic immunosuppressive mechanisms to enhance efficacy of immune checkpoint blockade in lung cancer
U.S. Department of Defense · 2019–2022
No publications yet
W81XWH1910286
KP
Clinical and Translational Science Center - KL2
National Center for Advancing Translational Sciences · 2017–2022Career
KL2TR002385-01
Co-I
The Role of RNA Methylation in Breast Cancer
U.S. Department of Defense · 2019–2022
No publications yet
W81XWH1910118
KP
Role of ER Stress-Driven IRE1a-XBP1 Signaling in Lung Cancer Pathogenesis
National Cancer Institute · 2017–2021Fellowship
F31CA217032-02
PI
Targeting Neutrophil Protease-Mediated Degradation of Tsp-1 to Induce Metastatic Dormancy
U.S. Department of Defense · 2016–2020
W81XWH-16-1-0615
KP
SPORE in Bladder Cancer
National Cancer Institute · 2018–2020 · via Sloan-Kettering Institute for Cancer Research
P50CA221745-02
KP
The role of EZH2 histone methyltransferase in triple negative breast cancer metastasis
PhRMA Foundation · 2018–2020Fellowship
PF-180597
MPI
Modeling Tumor-Stroma Crosstalk in Lung Cancer to Identify Targets for Therapy
National Cancer Institute · 2015–2020 · via Methodist Hospital Research Institute
U01CA188388-05
PI
Identification and Targeting of Metastasis Suppressing miRNAs in Triple Negative Breast Cancer
U.S. Department of Defense · 2016–2020
W81XWH-16-1-0065
PI
Targeting epigenetic regulator PRC2 as a therapy for established metastasis
METAvivor Research and Support, Inc. · 2018–2020
MRS 183299-02
KP
ART1: A Novel Therapeutic Target For the Prevention of Metastases From Non-Small Cell Lung Cancer
Free to Breathe · 2015–2019
FTB 16010147-03
PI
Inhibition of the IRE1alpha -XBP1 axis in lung cancer
Quentis Therapeutics · 2018–2019Contract
BP 184098-01
MPI
Mechanisms of Copper Depletion in TNBC Metastasis - From Bedside to the Bench
National Cancer Institute · 2017–2018 · via Cornell University - Ithaca
U54CA210184-02
Sub-PI
The Role of Endothelial Progenitor Cells in Tumor Growth and Metastasis
National Cancer Institute · 2008–2016 · via Sloan-Kettering Institute for Cancer Research
R01CA107429-10
MPI
Center for Systematic Modeling of Cancer Development
National Cancer Institute · 2012–2016 · via Methodist Hospital Research Institute· 2 renewals
U54CA149196-05 EW
PI
Molecular Mechanisms of Tumor-Initiated Premetastatic Niche Formation in Lung Stroma
National Cancer Institute · 2010–2015
R01CA135417-05 EW
KP
Center on the Microenvironment and Metastasis
National Cancer Institute · 2009–2015 · via Cornell University - Ithaca
U54CA143876-05 EW
Sub-PI
Center for Transport Oncophysics: PSOC Outreach Pilot Project - Overcoming Barriers in Pleural Malignancies With Multistage Nanovectors
National Cancer Institute · 2013–2014 · via Methodist Hospital Research Institute
U54CA143837-06
KP
Contribution of the Vascular Niche to the Hematopoietic Reconstitution
National Heart, Lung, and Blood Institute · 2009–2013
R01HL097797-03
Sub-PI
Microfluidic Tumor Models to Analyze the Role of Physiochemical Cues in the Agniogenic Switch
National Cancer Institute · 2009–2011 · via Cornell University - Ithaca
RC1CA146065-02EWO
PI
ANALYSIS OF Id GENE TARGETS IN TUMOR ENDOTHELIAL CELLS
NCI · 2004–2010 · via NIH RePORTER
R01CA100933-06

Clinical research

Completed & closed trials (1)

PI
Targeting Tumor-Intrinsic Immunosuppressive Mechanisms to Enhance Efficacy of Immune Checkpoint Blockade in Lung Cancer
Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2023)

Available technologies

2 View full WCM portfolio ↗

News mentions

9 View all WCM news ↗

Study Finds Restoring Order to Dividing Cancer Cells May Prevent Metastasis
October 3, 2025
Triple negative breast cancer (TNBC) is one of the most aggressive and hardest to treat breast cancers, but a new study led by Weill Cornell Medicine suggests a way to stop it from spreading.
Metabolic Reprogramming of T cells May Enhance Checkpoint Inhibitor Therapy
September 26, 2024
Stimulating a key metabolic pathway in T cells can make them work more effectively against tumors when combined with immune checkpoint inhibitor therapy, according to a preclinical study led by researchers at Weill Cornell Medicine.
Department of Defense Grant Awarded to Study Metastasis in Bladder Cancer
October 3, 2023
A Weill Cornell Medicine researcher has received a $610,000 grant from the Department of Defense to investigate the mechanisms causing DNA instability that potentially drives metastasis in bladder cancer.
Scientists Detail Major Mechanism Lung Cancers Use to Evade Immune Attack
January 10, 2023
A protein commonly found at high levels in lung cancer cells controls a major immunosuppressive pathway that allows lung tumors to evade immune attack.
NIH Grant Funds Cancer Prevention Vaccine Research
November 11, 2022
A multidisciplinary team of Weill Cornell Medicine researchers has received a five-year $5.7 million grant from the National Cancer Institute at the National Institutes of Health to fund a center aimed at developing messenger RNA (mRNA) vaccines to deter cancer development in at-risk groups.

Show 4 more mentions

Reducing Copper in the Body Alters Cancer Metabolism to Reduce Risk of Aggressive Breast Cancer
December 15, 2021
Depleting copper levels may reduce the production of energy that cancer cells need to travel and establish themselves in other parts of the body by a process referred to as metastasis.
Scientists Find a New Way to Reverse Immune Suppression in Tumors
September 20, 2021
Malignant tumors can enhance their ability to survive and spread by suppressing antitumor immune cells in their vicinity, but a study led by researchers at Weill Cornell Medicine and NewYork-Presbyterian has uncovered a new way to counter this immunosuppressive effect.
Cancer Moonshot Grant Funds Research into Discovering Targets for Lung Cancer Prevention Strategies
November 21, 2019
A prestigious Cancer Moonshot grant from the National Cancer Institute’s Immuno-Oncology Translational Network will enable investigators to explore the mechanisms that allow slow-growing lung cancer lesions to progress into aggressive malignancies and identify new therapeutic strategies to intercept the transition.
In Brief: Gold Nanoparticle Delivery of MicroRNA Impairs Metastasis in Triple-Negative Breast Cancer
April 11, 2019
Weill Cornell Medicine researchers have shown that giving mice with triple-negative breast cancer therapeutic microRNA (miRNA) in a protective gold nanoparticle results in significantly less spreading of cancer to the lung.

Mentoring

12 All publications with mentees →

6 PhD students · 6 Postdocs